CADTH
pan-Canadian Pharmaceutical Alliance (pCPA): January 2021 Trends and Insights January 2021 Highlights: 4 products completed CADTH review 9 products initiated pCPA negotiations 5 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation Files Under pCPA Consideration: CADTH issued 4 new recommendations & notifications to implement in January (29 files under pCPA consideration as of January 31) – down from…
MORSE Consulting is pleased to release our Fourth Annual pCPA Year in Review Infographic – 2020 Edition. This resource is aimed at helping market access stakeholders understand the top-line pCPA highlights from 2020. This infographic compares year-over-year metrics including: pCPA activity summary; the effect of COVID-19 on under-consideration files; average time to complete a negotiation; and files adjudicated by the pCPA by type in 2020. This infographic is an excerpt…
pan-Canadian Pharmaceutical Alliance (pCPA): December 2020 Trends and Insights December 2020 Highlights: 8 products completed CADTH review 2 products initiated pCPA negotiations 4 negotiations were completed with an LOI 1 negotiation was closed without an LOI 0 files were closed without negotiation Beginning this month and over the next few months, the pCPA is introducing a Targeted Negotiation Process (TNP) to address selected files that have been on hold…
pan-Canadian Pharmaceutical Alliance (pCPA): November 2020 Trends and Insights November 2020 Highlights: 4 products completed CADTH review 8 products initiated pCPA negotiation 5 negotiations were completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation Files Under pCPA Consideration: CADTH issued 4 new recommendations & notifications to implement in November (24 files under pCPA consideration as of November 30) – down…
pan-Canadian Pharmaceutical Alliance (pCPA): October 2020 Trends and Insights October 2020 Highlights: 5 products completed CADTH review 7 products initiated pCPA negotiations 5 negotiations were completed with an LOI 0 negotiations were closed without an LOI 2 files were closed without negotiation Files Under pCPA Consideration: CADTH issued 5 new recommendations in October (22 files as of October 31). PRODUCT INDICATION SPONSOR Type REC’N* DATE Xtandi** (enzalutamide) Metastatic…
pan-Canadian Pharmaceutical Alliance (pCPA): September 2020 Trends and Insights September 2020 Highlights: 1 product completed CADTH review 0 products initiated pCPA negotiations 2 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation Files Under pCPA Consideration: CADTH issued 1 new recommendation in September (25 files as of September 30). PRODUCT INDICATION SPONSOR HTA REC’N* DATE Zejula (niraparib) Ovarian…
pan-Canadian Pharmaceutical Alliance (pCPA): August 2020 Trends and Insights August 2020 Highlights: 2 products completed CADTH review 2 products initiated pCPA negotiations 1 negotiation was completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation Files Under pCPA Consideration: CADTH issued 2 new recommendations in August (25 files as of August 31). PRODUCT INDICATION SPONSOR HTA REC’N* DATE Soliris (eculizumab) Neuromyelitis…
Toronto, September 9, 2020 – MORSE Consulting is pleased to announce that Sal Cimino has joined our team as Senior Consultant, Private Drug Plans. The private payer market is playing an increasingly important role in ensuring a product’s reimbursement success in Canada. With the introduction of new specialty biologics and gene therapies, private payers are turning to new cost containment strategies that strongly resemble the public payer market. Private payers…
pan-Canadian Pharmaceutical Alliance (pCPA): July 2020 Trends and Insights July 2020 Highlights: 6 products completed CADTH review 6 products initiated pCPA negotiations 7 negotiations were completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation Trends are beginning to emerge regarding impact of COVID19 on pCPA negotiations with 3 months of experience to consider. In general, negotiations are taking longer to start…
pan-Canadian Pharmaceutical Alliance (pCPA): June 2020 Trends and Insights June Highlights: 4 products completed CADTH review 7 products initiated pCPA negotiations 4 negotiations were completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation Files Under pCPA Consideration: CADTH issued 4 new recommendations in June (23 files as of June 30). PRODUCT INDICATION SPONSOR HTA REC’N* DATE Cuvposa (glycopyrrolate) Chronic severe…
Consultations on Enhanced and Aligned Review Processes and Program Updates. CADTH released its Pharmaceutical Reviews Update — Issue 16 on June 25, 2020. It includes two consultations with respect to enhanced and aligned review processes, in addition to program update announcements. Highlights of the consultations and program updates are described below. Topic MORSE Note Consultations – Feedback due to CADTH by August 10, 2020 Consultation on Alignment of…
pan-Canadian Pharmaceutical Alliance (pCPA): May 2020 Trends and Insights May Highlights: 8 products completed CADTH review 5 products initiated pCPA negotiations 0 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation There was an evident slow down in May as the pCPA continues to adjust to the evolving COVID-19 situation. Â No negotiations were completed or closed for the first…
pan-Canadian Pharmaceutical Alliance (pCPA): April 2020 Trends and Insights April Highlights: 6 products completed CADTH review 4 products initiated pCPA negotiations 11 negotiations were completed with an LOI 2 negotiations were closed without an LOI 2 files were closed without negotiation In keeping with pCPA’s communication to industry associations, early trends into their management of files during the challenges associated with COVID indicate that initial priority has been on…
CADTH recently released their annual business plan for 2020-2021. In this, the last year of their three-year strategic plan, CADTH aims to deliver on a number of priority initiatives, several of which may have implications for industry, as described below. 1) Operationalize the Life Cycle Approach to Health Technology Assessment (HTA) Under this priority initiative, CADTH signals their continued commitment to the life cycle approach to HTA via: enhancement…
CADTH released its Pharmaceutical Reviews Update — Issue 15 on April 29, 2020. Please find below MORSE Consulting’s summary of this update. Topic MORSE Note 1. COVID-19 Update CADTH will continue to deliver on core activities, including the completion of ongoing drug reviews and initiation of new reviews in accordance with target timelines, and progress reports will continue to be posted on the CADTH website. Pre-submission and expert committee meetings…
Contact Us
MORSE Consulting Inc.
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
CADTH - Info and details on - Page 3 of 6 - MORSE Consulting Inc.
